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Abstract
Background: Hypoxia-induced mitogenic factor (HIMF) is developmentally regulated and plays an
important role in lung pathogenesis. We initially found that HIMF promotes vascular tubule
formation in a matrigel plug model. In this study, we investigated the mechanisms which HIMF
enhances expression of vascular endothelial growth factor (VEGF) in lung tissues and epithelial
cells.
Methods: Recombinant HIMF protein was intratracheally instilled into adult mouse lungs, VEGF
expression was examined by immunohistochemical staining and Western blot. The promoter-
luciferase reporter assay, RT-PCR, and Western blot were performed to examine the effects of
HIMF on VEGF expression in mouse lung epithelial cell line MLE-12. The activation of NF-kappa B
(NF-κB) and phosphorylation of Akt, IKK and IκBα were examined by luciferase assay and Western
blot, respectively.
Results: Intratracheal instillation of HIMF protein resulted in significant increase of VEGF, mainly
localized to airway epithelial and alveolar type II cells. Deletion of NF-κB binding sites within VEGF
promoter abolished HIMF-induced VEGF expression in MLE-12 cells, suggesting that activation of
NF-κB is essential for VEGF upregulation induced by HIMF. Stimulation of lung epithelial cells by
HIMF resulted in phosphorylation of IKK and IκBα, leading to activation of NF-κB. In addition,
HIMF strongly induced Akt phosphorylation, and suppression of Akt activation by specific inhibitors
and dominant negative mutants for PI-3K, and IKK or IκBα blocked HIMF-induced NF-κB activation
and attenuated HIMF-induced VEGF production.
Conclusion: These results suggest that HIMF enhances VEGF production in mouse lung epithelial
cells in a PI-3K/Akt-NF-κB signaling pathway-dependent manner, and may play critical roles in
pulmonary angiogenesis.
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Introduction
Vascular endothelial growth factor (VEGF), a dimeric 42-
kd protein, is a multifunctional cytokine that plays a piv-
otal role in angiogenesis [1]. Expression of VEGF has been
localized to perivascular cells in many organs, including
the lung, and is critical for normal pulmonary vascular
development [2]. Lacking even one allele of the VEGF
gene leads to embryonic lethality with impaired vessel for-
mation, and delayed endothelial cell development, and
vessel sprouting, remodeling, and survival are also
impaired [3,4]. VEGF is highly expressed by lung epithe-
lial cells and plays an important role in maintenance of
the differentiated state of blood vessels in pulmonary vas-
cular beds [5,6]. VEGF acts mainly through two tyrosine
kinase receptors, Flt-1 (VEGFR-1) and Flk-1 (VEGFR-2).
Flk-1 is expressed in the vascular endothelium and is the
earliest known marker for endothelium and endothelial
precursors [7]. A null mutation in Flk-1 leads to the lack
of a vasculature and results in very few endothelial cells,
suggesting that Flk-1 functions in the differentiation and/
or proliferation of endothelial cells [8]. In contrast, mice
deficient of Flt-1 have excess endothelial cells that are not
organized into normal tubular networks [9]. Since the
importance of VEGF and its receptor in lung angiogenesis,
development, and function maintenance, significant
efforts have been made to elucidate the mechanisms that
regulate their expression.
Hypoxia-induced mitogenic factor (HIMF) is a protein
originally discovered in a mouse model of hypoxia-
induced pulmonary hypertension [10]. Subsequent stud-
ies showed that HIMF is a lung-specific growth factor par-
ticipating in lung cell proliferation and modulation of
compensatory lung growth [10,11]. This cytokine-like fac-
tor possesses an angiogenic function that promotes vascu-
lar tubule formation in a matrigel plug model [10], and is
developmentally regulated [12]. In addition, in cultured
embryonic lung, HIMF exhibits antiapoptotic functions
[12]. Our earlier studies have discovered that intratracheal
instillation of recombinant HIMF protein induces wide-
spread proliferation of airway epithelial cells, alveolar
type II (ATII) cells, and cells in the lung parenchyma [11].
In this study, we further investigated the role of HIMF on
VEGF expression in mouse lungs, and in cultured lung
epithelial cells.
Materials and methods
Animal experiments
Adult male C57BL/6 mice (10–12 weeks old) were
obtained from Jackson Laboratories (Bar Harbor, ME).
Recombinant HIMF protein purification and HIMF intrat-
racheal instillation were performed as previously reported
[10,11]. All experiments followed the protocols approved
by the Animal Care and Use Committee of Johns Hopkins
University.
Immunohistochemical staining for VEGF
Lung samples were processed and immunostained as pre-
viously described [10,12]. Polyclonal antibody for VEGF
(1:200 dilution) was obtained from Santa Cruz Biotech-
nology (Santa Cruz, CA).
Western blot for HIMF, VEGF, and GAPDH
Tissue collection, homogenization and protein electro-
phoresis were performed as previously described [11,12].
Protein (50 µg) or 40 µl of medium supernatant (for
HIMF expression assay in cultured cells) from each sam-
ple was subjected to 4–20% pre-cast polyacrylamide gel
electrophoresis (Bio-Rad, Hercules, CA). HIMF, VEGF,
and GAPDH were detected with 1:1000, 1:500, and
1:1000 dilutions of antibodies, respectively, followed by
1:3000 dilution of goat anti-rabbit HRP-labeled antibody
(Bio-Rad). ECL substrate kit (Amersham, Piscataway, NJ)
was used for the chemiluminscent detection of the signals
with autoradiography film (Amersham).
Semi-quantitative RT-PCR for HIMF and VEGF
Total RNA was isolated with RNeasy Mini Kit (Qiagen
Inc., Valencia, CA). The reverse transcription reactions
were conducted with Transcriptor First Strand cDNA Syn-
thesis Kit (Roche, Indianapolis, IN). The PCR primers
were the following: for mouse HIMF 5'-ATGAAGACTA-
CAACTTGTTCCC-3' (positions 104 to 125 of second
exon) and 5'-TTAGGACAGT TGGCAGCAGCG-3' (posi-
tions 419 to 439 of fourth exon) amplifying a 336-bp frag-
ment; for mouse VEGF 5'-TGGATGTCTACCAGCGAAGC-
3' and 5'-ACAAGGCTCACAGTGATTT T-3' amplifying a
308-bp fragment between positions 522 and 829; for
mouse GAPDH, 5'-GCCAAGGTCATCCAT-
GACAACTTTGG-3' and 5'-GCCTGCTTCACCACCTTCTT-
GATG TC-3' amplifying a 314-bp fragment between
positions 532 and 845. The ratios between the amplified
DNA fragments and GAPDH for each sample RNA were
quantified by Phoretix 1 D software (Phoretix Interna-
tional Ltd., Newcastle upon Tyne, UK).
Cell culture and stimulation with HIMF
MLE-12 cells (ATCC, CRL 2110), an SV40-transformed
mouse lung epithelial cell line of alveolar type II cell line-
age, were grown in RPMI 1640 medium (Gibco, Grand
Island, NY) containing 10% fetal bovine serum (FBS,
Gibco), penicillin (100 U/ml) and streptomycin (100 µg/
ml). After the cells reached 80–90% confluency, the cells
were fed with a medium supplemented with 0.1% FBS
and 2 mmol/L L-glutamine. Thirty-three hours later, cells
were incubated in serum-free either RPMI 1640 for 4 h,
and pretreated with LY294002, SB203580, PD98059 or
U0126 (Calbiochem, La Jolla, CA) as indicated, then stim-
ulated with different concentrations of HIMF protein for
specified periods, with or without Actinomycin D (5 µg/
ml, Sigma, St. Louis, MO).Respiratory Research 2006, 7:37 http://respiratory-research.com/content/7/1/37
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HIMF enhances VEGF expression in mouse lungs Figure 1
HIMF enhances VEGF expression in mouse lungs. Recombinant HIMF protein was intratracheally instilled into adult 
mice (200 ng/animal in 40 µl saline, n = 6 for each group). The vehicle controls were instilled with saline (40 µl/animal, n = 3). 
Six and twenty four hours later, the mouse lungs were collected. (A) The immunohistochemical staining results indicated that 
HIMF protein instillation resulted in a significant increase of VEGF production, mainly located at alveolar type II (left panels, 
arrows) and airway epithelial cells (right panels, arrows). Scale bars: 100 µm. (B) Western blot indicated that VEGF expression 
was enhanced in HIMF-instilled mouse lungs. The symbol (*) indicates a significant increase from control mouse lungs instilled 
with saline only (P < 0.05).
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Establishment of stable HIMF overexpressing cell lines
Mouse HIMF cDNA was amplified from mouse lung tis-
sue and subcloned into pcDNA3.1/Zeo (+) (Invitrogen,
Carlsbad, CA). The primers used for the HIMF cDNA
amplification were sense 5'-CACCATGAAGACTA-
CAACTTGTTCCC-3' and antisense 5'-TTAGGACAGTT-
GGCAGCAGCG-3'. Dominant-negative mutants of IKKα
[IKKα (K44A)], IKKβ [IKKβ (K44A)], IκBα super-repressor
[IκBα (S32A/S36A)] and phosphatidylinositol 3-kinase
(PI-3K) (∆p85) were previously described [13,14]. HIMF
cDNA or dominant-negative mutants were transfected
into MLE-12 cells with Lipofectamine 2000 (Life Technol-
HIMF induces VEGF expression in mouse lung epithelial cell line Figure 2
HIMF induces VEGF expression in mouse lung epithelial cell line. MLE-12 cells were treated with HIMF for various 
concentrations and periods as indicated. Western blots and semi-quantitative RT-PCR were performed for VEGF expression. 
(2A) HIMF induced VEGF protein and mRNA production in a dose-dependent manner in MLE-12 cells. (2B) Time-course study 
indicated that HIMF (40 nmol/L)-induced VEGF production started at 6 h, and persisted for 24 h. Triplicate experiments were 
performed with essentially identical results.Respiratory Research 2006, 7:37 http://respiratory-research.com/content/7/1/37
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Generation of HIMF overexpressing cells Figure 3
Generation of HIMF overexpressing cells. MLE-12 cells were transfected with HIMF cDNA or control vector. Stable cell 
lines, MLE-HIMF, along with their transfection control cells MLE-Zeo, were screened based on resistance to Zeocin (400 µg/
ml). Western blots with cell culture medium for HIMF and protein from cell lysate for VEGF (3A) and RT-PCR with cell total 
RNA (3B) demonstrated that MLE-HIMF have higher HIMF protein and mRNA levels than their parent (MLE-12) and transfec-
tion (MLE-Zeo) counterparts. The VEGF levels in MLE-HIMF were also increased significantly compared with those of their 
controls. The symbol (*) indicates a significant increase from parent controls (P < 0.05). Triplicate experiments were per-
formed with essentially identical results.Respiratory Research 2006, 7:37 http://respiratory-research.com/content/7/1/37
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HIMF increases the transcription activities, but not mRNA stability of VEGF in MLE-12 cells Figure 4
HIMF increases the transcription activities, but not mRNA stability of VEGF in MLE-12 cells. (4A) MLE-12 cells 
were co-transfected with pGL-VEGF and pRL-TK. Twenty-four hours later, the cells were incubated with HIMF protein as indi-
cated. Then, cells were lysed with passive lysis buffer, and luciferase activity was measured according to the dual-luciferase 
assay manual. The time-course study demonstrated that HIMF-induced (40 nmol/L) VEGF transcription started at 6 h, and per-
sisted for 24 h. After incubation with 10–80 nmol/L of HIMF, VEGF transcripts in MLE-12 were enhanced in a dose-dependent 
manner. (4B) MLE-12 were treated with different concentrations of HIMF and incubated with 5 µg/ml of Actinomycin D for 4, 
8 and 16 h. RT-PCR indicated that HIMF did not prevent Actinomycin D-facilitated VEGF degradation in MLE-12 cells. The 
symbol (*) indicates a significant increase from MLE-12 controls without HIMF (P < 0.05). Triplicate experiments were per-
formed with essentially identical results.Respiratory Research 2006, 7:37 http://respiratory-research.com/content/7/1/37
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Promoter deletion assay for HIMF-induced VEGF expression in MLE-12 cells Figure 5
Promoter deletion assay for HIMF-induced VEGF expression in MLE-12 cells. MLE-12 cells were co-transfected 
with pRL-TK and each VEGF luciferase reporter construct (5A) for 24 h, then cells were incubated with HIMF protein (40 
nmol/L) for another 24 h. Luciferase activity was measured and the firefly luciferase signal was normalized to the renilla luci-
ferase signal for each individual well. (5B) Deletion of NF-κB binding site, but not HRE or binding sites for AP-1 and AP-2, com-
pletely abolished HIMF-induced VEGF promoter activity. Deletion of all cis-acting elements resulted in complete loss of 
induction of VEGF promoter activity. The symbol (*) indicates a significant increase from MLE-12 controls untreated with 
HIMF (P < 0.05). The symbol (#) indicates a significant decrease from MLE-12 transfected with pGL-VEGF and treated with 
HIMF (P < 0.05). Triplicate experiments were performed with essentially identical results.Respiratory Research 2006, 7:37 http://respiratory-research.com/content/7/1/37
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ogies, Inc., Gaithersburg, MD). Stable cell lines, MLE-
HIMF, and their transfection control (vector only) cells
MLE-Zeo, were selected with Zeocin (400 µg/ml). HIMF
expression was validated by Western blotting and RT-PCR
analyses.
Dual-luciferase reporter assay for VEGF and NF-κB
The mouse VEGF promoter-luciferase reporter constructs
containing a series of deletion fragments from the 5'-
flanking region of VEGF promoter, pGL-VEGF, pGL-VEGF
(-HRE), pGL-VEGF (-AP1), pGL-VEGF (-AP2), pGL-VEGF
(-NFκB) and pGL-VEGF (-SP1), were provided by Dr. S.
Joseph Leibovich (Department of Cell Biology and Molec-
ular Medicine, New Jersey Medical School, NJ) [15]. The
NF-κB luciferase reporter construct pNFκB-Luc was pur-
chased from Stratagene (La Jolla, CA). Cells were co-trans-
fected with each reporter construct and the renilla
luciferase vector pRL-TK (Promega, Madison, WI), with or
without HIMF protein stimulation, and treated with pas-
sive lysis buffer according to the dual-luciferase assay
manual (Promega). The luciferase activity was measured
with a luminometer (Lumat LB9507, Berthold Tech., Bad
Wildbad, Germany). The firefly luciferase signal was nor-
malized to the renilla luciferase signal for each individual
analysis.
Phosphorylation Assay for IKK, IκBα and Akt
MLE-12 cells were treated with HIMF as described above.
Protein (50 µg) from each sample was subjected to 4–
20% pre-cast polyacrylamide gel (Bio-Rad) electrophore-
sis and transferred to nitrocellulose membranes (Bio-
Rad), and then probed with rabbit anti-mouse antibodies
against phospho-specific and non-phosphorylated IKK,
IκBα and Akt (1:500 dilution, Santa Cruz Biotechnology),
followed by 1:3000 dilution of goat anti-rabbit HRP-
labeled antibody (Bio-Rad). ECL substrate kit (Amer-
sham) was used for the chemiluminscent detection of the
signals with autoradiography film (Amersham).
Statistical analysis
Unless otherwise stated, all data were shown as mean ±
standard error of the mean (SEM). Statistical significance
(P < 0.05) was determined by t test or analysis of variance
(ANOVA) followed by assessment of differences using Sig-
maStat 2.03 software (Jandel, Erkrath, Germany).
Results
HIMF enhances VEGF expression in mouse lungs
To examine the role of HIMF in VEGF expression in the
lung, we intratracheally instilled recombinant HIMF pro-
tein into adult mouse lungs. We found that VEGF expres-
sion was significantly enhanced by HIMF stimulation, as
demonstrated by immunohistochemical staining (Fig.
1A). The expressed VEGF was mainly localized within ATII
and airway epithelial cells. Western blotting further con-
firmed the upregulation of VEGF in lung tissues after 6–24
h of HIMF-instillation (Fig. 1B).
HIMF upregulates VEGF expression in mouse lung 
epithelial cells
Although HIMF treatment leads to upregulation of VEGF,
molecular mechanisms governing such induced expres-
sion in lung tissues remain unclear. To establish a cellular
system for further investigating regulatory mechanisms of
HIMF-induced VEGF production, we selected cultured
MLE-12 (epithelial) cells as models. Western blotting of
cell lysates showed that HIMF induces VEGF production
in a dose-dependent manner in MLE-12 (Fig. 2A). These
findings are consistent with the observations in lung tis-
sues (Fig 1A). The induced expression of VEGF was further
confirmed by RT-PCR in MLE-12 cells (Fig. 2A). Time-
course studies showed that HIMF-induced VEGF produc-
tion appeared at 6 h, and the expression level sustained
for 24 h (Fig. 2B). VEGF also expresses to an elevated level
in a cell line, MLE-HIMF that stably expresses HIMF (Fig.
3A and 3B). Successful recapitulation of HIMF-induced
VEGF expression in epithelial cell line provides the basis
for further dissecting the molecular mechanism of HIMF-
induced upregulation of VEGF.
HIMF modulates VEGF transcription, not its mRNA 
stability
To test whether HIMF enhances VEGF expression at tran-
scriptional level, we used a reporter construct, pGL-VEGF,
which contains a luciferase gene driven by the VEGF pro-
moter. The reporter plasmid was transiently transfected
into MLE-12 cells and HIMF treatment of the transfected
cells induced significant increases of luciferase activity in
a dose-dependent manner (Fig 4A). It has been reported
that VEGF mRNA stability is an important posttranscrip-
tional parameter that modulates VEGF expression [16]. It
is, therefore, possible that HIMF treatment enhances
VEGF mRNA stability. To test this possibility, we used
Actinomycin D, a transcription inhibitor that blocks tran-
scription. However, VEGF mRNA degradation was still
observed when treatment of MLE-12 cells with HIMF and
Actinomycin D (Fig. 4B). These observations suggest that
HIMF does not influence VEGF mRNA stability and the
regulation of VEGF expression by HIMF is at transcrip-
tional, rather than posttranscriptional level.
Activation of NF-κB is essential for HIMF-induced VEGF 
expression
After established that HIMF enhances VEGF expression at
transcriptional level, we further explored the transcription
factor(s) involved in the regulation. We used a series of
luciferase reporter constructs containing different deletion
segments of mouse VEGF promoter sequence [15], includ-
ing hypoxia response element (HRE) and binding sites for
AP-1, AP-2, NF-κB, and SP-1 (Fig. 5A). As shown in Fig.Respiratory Research 2006, 7:37 http://respiratory-research.com/content/7/1/37
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HIMF activates NF-κB in MLE-12 cells Figure 6
HIMF activates NF-κB in MLE-12 cells. Cells were co-transfected with pNFκB-luc and pRL-TK, with or without stimula-
tion of HIMF protein for various periods as indicated. (6A) Dual-luciferase assay indicated that MLE-HIMF had higher NF-κB 
activity than their control counterparts. (6B) Dual-luciferase assay indicated that HIMF protein increased the NF-κB activity in 
MLE-12 cells in a dose-dependent manner. The symbol (*) indicates a significant increase from MLE-12 parent controls or con-
trols untreated with HIMF (P < 0.05). Triplicate experiments were performed with essentially identical results.Respiratory Research 2006, 7:37 http://respiratory-research.com/content/7/1/37
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Activation of NF-κB is essential for HIMF-induced VEGF expression Figure 7
Activation of NF-κB is essential for HIMF-induced VEGF expression. Cells were co-transfected with pNFκB-luc, 
dominant-negative mutants of NF-κB pathway and pRL-TK, with or without stimulation of HIMF protein for various periods as 
indicated. (7A) Western blots indicated that HIMF (40 nmol/L) induced phosphorylation of IKK and IκBα in MLE-12 cells. (7B 
and 7C) Transfection of MLE-12 cells with dominant-negative mutants IKKα (K44A) and IKKβ (K44A), and super-repressor 
IκBα (S32A/S36A), abolished HIMF (40 nmol/L)-induced NF-κB activity and upregulation of VEGF in MLE-12 cells. The symbol 
(*) indicates a significant increase from MLE-12 controls untreated with HIMF (P < 0.05). The symbol (#) indicates a significant 
decrease from MLE-12 cells treated with HIMF only (P < 0.05). Triplicate experiments were performed with essentially identi-
cal results.
C
o
n
t
r
o
l
H
I
M
F
3
0
m
i
n
H
I
M
F
6
0
m
i
n
H
I
M
F
1
8
0
m
i
n
 
H
I
M
F
3
6
0
m
i
n
IkK
MLE-12  Western blot
P-IkK
P-Iκ κ κ κBα α α α
GAPDH
HIMF(40 nM) –+   + +    +    +       HIMF (40 nM) – +      + +      +       +
Vector  – – +        – – – Vector – – +       – – –
∆ ∆ ∆ ∆ Ikkα α α α – – – +        – – ∆ ∆ ∆ ∆ Ikkα α α α – ––+  – –
∆ ∆ ∆ ∆ Ikkβ β β β – – ––+     – ∆ ∆ ∆ ∆ Ikkβ β β β –– –– +    –
∆ ∆ ∆ ∆ Iκ κ κ κBα α α α – – –––+       ∆ ∆ ∆ ∆ Iκ κ κ κBα α α α ––– – – +
0
1
2
3
4
5
R
e
l
a
t
i
v
e
 
N
F
-
k
a
p
p
a
 
B
 
A
c
t
i
v
i
t
y * *
*
#
#
#
*
*
#
#
#
0
1
2
3
4
5
6
7
R
e
l
a
t
i
v
e
 
V
E
G
F
 
T
r
a
n
s
c
r
i
p
t
s
*
*
C
o
n
t
r
o
l
H
I
M
F
H
I
M
F
+
p
E
V
R
F
 
H
I
M
F
+
 
∆
∆
∆
∆
I
k
k
α
α
α
α
H
I
M
F
+
 
∆
∆
∆
∆
I
k
k
β
β
β
β
H
I
M
F
+
 
∆
∆
∆
∆
I
 
κ
κ
κ
κ
B
α
α
α
α
42 KD
37 KD
MLE-12  Western blot
GAPDH
VEGF
A
B
CRespiratory Research 2006, 7:37 http://respiratory-research.com/content/7/1/37
Page 11 of 14
(page number not for citation purposes)
HIMF-induced NF-κB activation and upregulation of VEGF is PI-3K/Akt pathway dependent Figure 8
HIMF-induced NF-κB activation and upregulation of VEGF is PI-3K/Akt pathway dependent. MLE-12 cells were 
pretreated with signal transduction inhibitors or co-transfected with luciferase constructs and PI-3K dominant-negative 
mutant, then stimulated with HIMF (40 nmol/L) for various periods as indicated. (8A) HIMF strongly induced the phosphoryla-
tion of Akt at Ser473 and Thr308. The Akt phosphorylation started at 30 minutes and sustained for 360 min. HIMF also 
induced phosphorylation of ERK1/2 and p38 MAPK, but not JNK MAPK in MLE-12 cells. (8B) The PI-3K inhibitor LY294002 
(10 µmol/L), but not SB203580 (5 µmol/L), PD098059 (5 µmol/L) or U0126 (5 µmol/L), abolished HIMF-induced Akt phospho-
rylation and upregulation of VEGF in MLE-12 cells. (8C) Transfection of ∆p85, into MLE-12 cells abolished HIMF-induced phos-
phorylation of IKK and IκBα, NF-κB activation and production of VEGF. The symbol (*) indicates a significant increase from 
MLE-12 controls without HIMF treatment (P < 0.05). The symbol (#) indicates a significant decrease from MLE-12 cells treated 
with HIMF only (P < 0.05). Triplicate experiments were performed with essentially identical results.
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5B, deletion of NF-κB binding site, but not HRE or bind-
ing sites for AP-1 and AP-2, completely abolished HIMF-
induced VEGF promoter activity in MLE-12 cells. It has
been reported that activation of NF-κB leads to the expres-
sion of VEGF [17]. We therefore tested whether HIMF
induction would lead to activation of NF-κB, and subse-
quently, the expression of VEGF, using luciferase reporter
assays. As shown in Fig. 6A, NF-κB activities in MLE-HIMF
were significantly higher than those of their control coun-
terparts. Consistent with the observation in MLE-HIMF
cell line, incubation of MLE-12 cells with HIMF protein
also induces NF-κB activity in a dose-dependent manner
(Fig. 6B).
The prerequisite of NF-κB activation is the signal-depend-
ent activation of the IKK-signalsome that contains IKKα
and β kinases and other regulatory components. The IKK
subsequently phosphorylates the inhibitor of NF-κB, IκB
(IκBα as the dominant form in majority of cells). The
phosphorylated IκBα is then degraded by the proteasome
and releases bound NF-κB into the nucleus, leading to κB
promoter/enhancer-specific gene expression. We found
that HIMF induces phosphorylation of IKK and IκBα in
MLE-12 cells (Fig. 7A), suggesting that HIMF signal goes
through NF-κB route. Transfection of dominant negative
mutants of IKK kinases, IKKα (K44A) and IKKβ (K44A),
and an IκBα super-repressor, IκBα (S32A/S36A), abol-
ished HIMF-induced NF-κB activity and production of
VEGF in MLE-12 cells (Fig. 7B and 7C). Together, these
findings demonstrated that activation of transcription fac-
tor NF-κB is essential for HIMF-induced VEGF produc-
tion.
PI-3K/Akt pathway is involved in HIMF-induced NF-κB 
activation and production of VEGF
It has been reported that HIMF also activates PI-3K/Akt
signaling pathway. It is unclear, though, whether there are
interplays between PI-3K/Akt and NF-κB pathways, and
whether such interplays are necessary for HIMF-induced
VEGF production. We therefore first tested the activation
of main components of PI-3K/Akt signaling pathway
upon HIMF treatment by Western blotting. As shown in
Fig. 8A, HIMF strongly induces the phosphorylation of
Akt at Ser473 and Thr308, ERK1/2 and p38 MAPK, but
not JNK MAPK in MLE-12 cells. The Akt activation
appeared at 30 min upon HIMF treatment, and sustained
till 360 min. The PI-3K inhibitor LY294002 suppressed
HIMF-induced Akt phosphorylation and upregulation of
VEGF (Fig. 8B). Inhibitors to p38 and ERK1/2 MAPK path-
ways, SB203580, PD098059 or U0126, respectively, did
not block Akt phosphrylation and VEGF expression
induced by HIMF (Fig. 8B). Further, we found that trans-
fection of ∆p85, a dominant-negative mutant of PI-3K,
into MLE-12 cells abolished HIMF-induced phosphoryla-
tion of IKK and IκBα (Fig. 8C), suggesting that PI-3K sig-
naling acts at upstream of IKK signalsome. Consisting
with this notion, ∆p85 blocked HIMF-induced NF-κB acti-
vation as demonstrated by reduced NF-κB luciferase activ-
ity, and the production of VEGF (Figs. 8C). Together, our
studies suggest that interplays between PI-3K/Akt and NF-
κB signaling pathways are essential for HIMF-induced
VEGF expression in lung epithelial cells.
Discussion
A role for VEGF signaling in lung vascular development is
suggested by the expression pattern of VEGF and its recep-
tors [18]. Epithelial cells express VEGF during the process
of lung morphogenesis, and the expression of its receptors
is found in mesenchymal cells [18,19]. The complemen-
tary expression of this ligand-receptor system suggests the
involvement of VEGF in the regulatory interactions
between epithelial and vascular cells during lung morpho-
genesis [18]. Our previous study showed that HIMF is not
expressed in the early pseudoglandular stage but begins at
the terminal sac and alveolar stages. HIMF expression con-
tinues to be markedly upregulated until postnatal day 30
[12]. The temporal and spatial expression of HIMF in the
perinatal period suggests its important roles as a coordina-
tor of epithelial and endothelial growth during lung peri-
natal development. In the present study, we found that
HIMF enhances VEGF production in mouse lung tissues
and epithelial cell line. In contrast, Flk-1 expresses in
endothelial cells, which can also be induced by HIMF via
the PI-3K/Akt and NF-κB signaling pathways (preliminary
studies, data not shown). Interestingly, HIMF-enhanced
expression of VEGF occurs in epithelial cells (Fig. 2 and
Fig. 6E), whereas Flk-1 induction occurs in endothelial
cells (data not shown), suggesting that additional tran-
scription factor(s) differentially regulates the cell type-spe-
cific expression VEGF and its receptor Flk-1. Identification
of these transcription factor(s) should contribute signifi-
cantly to our understanding of lung development and
pathogenesis and certainly warrant further study.
Up to now, the organization of regulatory elements
required for the expression of VEGF and Flk-1 has only
been partially defined [15,17]. Several cis-acting elements,
including the hypoxia response element (HRE) and bind-
ing sites for transcription factors, including AP-1, AP-2,
NF-κB, and SP-1, are present in the murine VEGF pro-
moter [15]. These elements are involved in the transcrip-
tional activation of VEGF gene expression by numerous
effectors, including hypoxia, growth factors and
cytokines, such as TGF-α, TGF-β, IL-1β, and IL-6 [17].
Analysis of these elements revealed that HRE is required as
a cis-element for transcriptional activation of VEGF by
either hypoxia or nitric oxide [15,20]. Transcription factor
AP-1 contributes to activation and expression of VEGF
gene in hypoxic conditions. However, AP-1 is not neces-
sary in the induction of VEGF gene expression [21]. NF-κBRespiratory Research 2006, 7:37 http://respiratory-research.com/content/7/1/37
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is involved in the upregulation of VEGF and its activity is
associated with the high expression of VEGF mRNA [22].
In this current study, we found that HIMF protein
enhances VEGF expression by inducing transcription fac-
tor NF-κB, that is required for VEGF promoter activity,
rather than stabilizing VEGF mRNA posttranscriptionally.
In resting cells, NF-κB is sequestered in the cytoplasm
through its interaction with the IκB (inhibitor of NF-κB)
family of inhibitory proteins [23]. In response to external
stimuli, IκB proteins undergo rapid phosphorylation on
specific serine residues. Phosphorylation of IκBα on ser-
ines 32 and 36 and of IκBβ on serines 19 and 23 facilitate
their ubiquitination on neighboring lysine residues,
thereby targeting these proteins for rapid degradation by
the proteosome [24]. Following the degradation of IκB,
NF-κB is released and is free to translocate to the nucleus
and to activate its cognate genes. A key regulatory step in
this pathway is the activation of a high molecular weight
IκB kinase (IKK) complex, termed IKK signalsome, in
which catalysis is carried out by multiple kinases includ-
ing IKKα and IKKβ [23]. Although NF-κB can be activated
by different stimuli, the IKK signalsome serves as the key
point that converges diverse upstream signals. In the
present study, we found that phosphorylation of IKK and
IκBα was induced by HIMF administration. Moreover,
transfection of the dominant-negative mutants of IKKα
and IKKβ, and an IκBα super-repressor abolished HIMF-
induced NF-κB activation. These data support the notion
that HIMF activates NF-κB through phosphorylation of
IKK and IκBα.
Substantial progress has been made in understanding the
signal transduction pathways regulating VEGF expression.
Phosphatidylinositol 3-kinase (PI-3K) is a lipid kinase
that is composed of two polypeptides, a p85 regulatory
subunit, and a p110 catalytic subunit and is activated by a
large spectrum of cytokines, hormones, and growth fac-
tors [25]. The serine-threonine kinase Akt is a downstream
target of PI-3K [26]. Akt is regulated by phosphorylation
at Thr308 and Ser473 residues by two phosphoinositide
dependent protein kinases, PDK1 and PDK2 [26]. Acti-
vated PI-3K and Akt are strong inducers of neovasculariza-
tion and endothelial cell proliferation [27]. VEGF levels
are elevated in cells expressing activated PI-3K and Akt
either by enhanced transcription or increased mRNA sta-
bility [27]. Our results demonstrated that HIMF induced
Akt phosphorylation in MLE-12 cells. The time course of
Akt phosphorylation is compatible with that of NF-κB
activation in HIMF stimulated cells. Pretreatment of cells
with LY294002, a PI-3K specific inhibitor, attenuated
HIMF-induced Akt phosphorylation. Further, transfection
of ∆p85, blocked HIMF-induced phosphorylation of the
IKK and IκBα, and hence NF-κB activation, and thus pre-
vented upregulation of VEGF. These results suggest that
PI-3K/Akt pathway is involved in HIMF-induced NF-κB
activation and production of VEGF in mouse epithelial
cells. Together, our studies identified a novel NF-κB acti-
vator, HIMF, and the upstream pathways that transduce
HIMF signals from cell surface to nucleus, leading to the
expression of VEGF.
In summary, our previous studies showed that HIMF pos-
sesses an angiogenic function that promotes vascular
tubule formation in a matrigel plug model [10]. The cur-
rent studies indicated that HIMF enhances VEGF produc-
tion in mouse lung tissues and epithelial cells in a PI-3K/
Akt-NF-κB signaling pathway-dependent manner, which
at least in part, elucidated the molecular mechanisms of
HIMF-elicited angiogenesis and contributed to a better
understanding of the function of HIMF in lung angiogen-
esis and in the maintenance of pulmonary vascular home-
ostasis.
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